Sulindac 100 mg - search results

puracap laboratories llc dba blu pharmaceuticals - sulindac (unii: 184sns8vuh) (sulindac - unii:184sns8vuh) - sulindac 150 mg - carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). sulindac is indicated for acute or long-term use in the relief of signs and symptoms of the following: 1. osteoarthritis 2. rheumatoid arthritis** 3. ankylosing spondylitis 4. acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis) 5. acute gouty arthritis **the safety and effectiveness of sulindac tablets usp have not been established in rheumatoid arthritis patients who are designated in the american rheumatism association classification as functional class iv (incapacitated, largely or wholly bedridden, or confined to wheelchair, little or no self-care). sulindac is contraindicated in patients with known hypersensitivity to sulindac or the excipients (see description ). sulindac should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic/anaphylactoid reactions to nsaids have been reported in such patients (see warnings – anaphylactic/anaphylactoid reactions , and precautions – preexisting asthma ). sulindac is contraindicated in the setting of coronary artery bypass graft (cabg) surgery (see warnings ).

United States - English - NLM (National Library of Medicine)

sulindac tablet

epic pharma, llc - sulindac (unii: 184sns8vuh) (sulindac - unii:184sns8vuh) - sulindac 150 mg - carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). sulindac is indicated for acute or long-term use in the relief of signs and symptoms of the following: 1. osteoarthritis 2. rheumatoid arthritis** 3. ankylosing spondylitis 4. acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis) 5. acute gouty arthritis **the safety and effectiveness of sulindac tablets usp have not been established in rheumatoid arthritis patients who are designated in the american rheumatism association classification as functional class iv (incapacitated, largely or wholly bedridden, or confined to wheelchair, little or no self-care). sulindac is contraindicated in patients with known hypersensitivity to sulindac or the excipients (see description ). sulindac should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic/anaphylactoid reactions to nsaids have been reported in such patients (see warnings – anaphylactic/anaphylactoid reactions , and precautions – preexisting asthma ). sulindac is contraindicated in the setting of coronary artery bypass graft (cabg) surgery (see warnings ).

United States - English - NLM (National Library of Medicine)

sulindac tablet

sun pharmaceutical industries, inc. - sulindac (unii: 184sns8vuh) (sulindac - unii:184sns8vuh) - sulindac 150 mg - carefully consider the potential benefits and risks of sulindac tablets and other treatment options before deciding to use sulindac tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). sulindac tablets are indicated for acute or long-term use in the relief of signs and symptoms of the following: sulindac tablets are contraindicated in patients with known hypersensitivity to sulindac or the excipients (see description ). sulindac tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic/anaphylactoid reactions to nsaids have been reported in such patients (see warnings – anaphylactic/anaphylactoid reactions , and precautions – preexisting asthma ).

New Zealand - English - Medsafe (Medicines Safety Authority)

aclin

viatris limited - sulindac 100mg; sulindac 100mg - tablet - 100 mg - active: sulindac 100mg excipient: lactose monohydrate magnesium stearate microcrystalline cellulose povidone purified talc quinoline yellow sodium starch glycolate active: sulindac 100mg excipient: lactose monohydrate magnesium stearate microcrystalline cellulose povidone purified talc quinoline yellow sodium starch glycolate - aclin is indicated for acute or long-term use in the treatment of the following: · osteoarthritis · rheumatoid arthritis · ankylosing spondylitis · periarticular diseases such as acute painful shoulder (acute subacromial bursitis/supraspinatus tendonitis) and tenosynovitis · acute gouty arthritis · painful low back syndrome (low back pain, commonly referred to as lumbago).